Inactivation of mycoplasma species in blood by INACTINE PEN110 process

Transfusion

Volumn 44, Issue 2, 2004, Pages 286-293

  Zavizion, Boris ^a   Purmal, Andrei ^a   Chapman, John ^a   Alford, Bernadette ^a  

^a VI Technologies Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOLOGIC AGENT; INACTINE; PEN 110; UNCLASSIFIED DRUG;

ANTIBACTERIAL ACTIVITY; ARTICLE; BACTERIUM CULTURE; BACTERIUM ISOLATE; BLOOD STORAGE; BLOOD TRANSFUSION; COLONY FORMING UNIT; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG EFFECT; ERADICATION THERAPY; ERYTHROCYTE TRANSFUSION; MYCOPLASMA; NONHUMAN; SAFETY; VIRUS INACTIVATION;

BLOOD BANKS; BLOOD PRESERVATION; CRYOPRESERVATION; ERYTHROCYTES; HUMANS; LEUKOCYTES; MYCOPLASMA ARTHRITIDIS; MYCOPLASMA INFECTIONS; POLYAMINES;

EID: 1242322068     PISSN: 00411132     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1537-2995.2004.00647.x     Document Type: Article

References (42)

1. Dodd RY. Bacterial contamination and transfusion safety: experience in The United States. Transfus Clin Biol 2003;10:6-9.
2. Kuehnert MJ, Roth VR, Haley NR, et al. Transfusion-transmitted bacterial infection in the United States, 1998 through 2000. Transfusion 2001;41:1493-9.
3. Leiby DA. Chlamydia pneumoniae: another agent added to the growing list of transfusion-transmitted pathogens. Transfusion 2003;43:552-5.
4. Kordick DL, Brown TT, Shin K, et al. Clinical and pathological evaluation of chronic Bartonella henselae or Bartonella clarridgeiae infection in cat. J Clin Microbiol 1999;37:1536-47.
5. Tully JG. Current status of the mollicute flora of humans. Clin Infect Dis 1993;17:S2-9.
6. Rosengarten R, Citti C, Much P, et al. The changing image of mycoplasmas: from innocent bystanders to emerging and reemerging pathogens in human and animal diseases. Contrib Microbiol 2001;8:166-85.
7. Baseman JB, Tully JG. Mycoplasmas, sophisticated, reemerging, and burdened by their notoriety. Emerg Infect Dis 1997;3:21-32.
8. Taylor P. Medical significance of mycoplasmas. Meth Mol Biol 1998;104:7-15.
9. Leong MA, Nachajon R, Ruchelli E, et al. Bronchitis obliterans due to Mycoplasma pneumonia. Pediatr Pulmonol 1997;23:375-81.
10. Bruch LA, Jefferson RJ, Pike MG, et al. Mycoplasma pneumoniae infection, meningoencephalitis, and hemophagocytosis. Pediatr Neurol 2001;25:67-70.
11. Bonilla HF, Chenoweth CE, Tully JG, et al. Mycoplasma felis septic arthritis in a patient with hypogammaglobulinemia. Clin Infect Dis 1997;24:222-5.
12. John SD, Ramanathan J, Swischuk LE. Spectrum of clinical and radiographic findings in pediatric mycoplasma pneumonia. Radiographics 2001;21:121-31.
13. Taylor-Robinson D. Mycoplasmagenitalium: an up-date. Int J STD AIDS 2002;13:145-51.
14. Vichinsky EP, Neumayr LD, Earles AN, et al. Causes and outcomes of the acute chest syndrome in sickle cell disease. N Engl J Med 2000;342:1855-65.
15. Choppa PC, Vojdani A, Tagle C, et al. Multiplex PCR for the detection of Mycoplasma fermentans, M. hominis and M. penetrans in cell cultures and blood samples of patients with chronic fatigue syndrome. Mol Cell Probes 1998;12:301-8.
16. Vojdani A, Choppa PC, Tagle C, et al. Detection of mycoplasma genus and Mycoplasma fermentans by PCR in patients with chronic fatigue syndrome. FEMS Immunol Med Microbiol 1998;22:355-65.
17. Haier J, Nasralla M, Franco AR, et al. Detection of mycoplasmal infections in blood of patients with rheumatoid arthritis. Rheumatology (Oxford) 1999;38:504-9.
18. Tully JG, Shih JW, Wang RH, et al. Titers of antibody to mycoplasma in sera of patients infected with human immunodeficiency virus. Clin Infect Dis 1993;17:S254-8.
19. Wang RY, Grandinetti T, Shih JW, et al. Mycoplasma genitalium infection and host antibody immune response in patients infected by HIV, patients attending STD clinics and in healthy blood donors. FEMS Immunol Med Microbiol 1997;19:237-45.
20. Lazo A, Tassello J, Jayarama V, et al. A broad spectrum virus reduction in red cell concentrates using INACTINE™ PEN110 Chemistry. Vox Sang 2002;83:313-23.
21. Ohagen A, Gibaja V, Aytay S, et al. Inactivation of the human immunodeficiency virus in blood. Transfusion 2002;42:1308-17.
22. Hope J, Roth N, Hagigi L, et al. High efficiency removal of prion proteins from red cell concentrates by the INACTINE™ process. Blood 2001;98:542a.
23. Purmal A, Zavizion B, Serebryanik D, et al. Removal of white blood cell and plasma proteins from leukofiltered red blood cell concentrates by INACTINE™ pathogen inactivation process. Transfusion 2001;41:90S.
24. Chapman J. Progress in improving the pathogen safety of red cell concentrates. Vox Sang 2000;78:203-4.
25. Purmal A, Valeri CR, Dzik W, et al. Process for the preparation of pathogen-inactivated RBC concentrates by using PEN110 chemistry: preclinical studies. Transfusion 2002;42:139-45.
26. AuBuchon JP, Pickard CA, Herschel LH, et al. Production of pathogen-inactivated RBC concentrates using PEN110 chemistry: a Phase I clinical study. Transfusion 2002;42:146-52.
27. Fast LD, DiLeone G, Edson CM, et al. Inhibition of murine GVHD by INACTINE™ PEN110 treatment. Transfusion 2002;42:1326-32.
28. Fast LD, DiLeone G, Edson CM, et al. PEN110 treatment functionally inactivates the PBMNCs present in RBC units: comparison to the effects of exposure to γ-irradiation. Transfusion 2002;42:1318-25.
29. Chapman J, Fisher B, Moor K. The viral inactivation compound INACTINE™ PEN110 lacks reproductive toxicity in rabbits. Vox Sang 2002;83:191.
30. Hemminki K. Reactions of ethyleneimine with guanosine and deoxyguanosine. Chem Biol Interacts 1984;48:249-60.
31. Budowsky EI, Zalesskaya MA, Nepomnyashchaya NM, et al. Principals of selective inactivation of the viral genome: dependence of the rate of viral RNA modification on the number of protonizable groups in ethyleneimine oligomers. Vaccine Res 1996;5:29-39.
32. O'Connor TR, Boiteux S, Laval J. Ring-opened 7-methylguanine residues in DNA are a block to in vitro DNA synthesis. Nucl Acid Res 1988;16:5879-94.
33. Perez P, Salmi LR, Follea G, et al. Determinants of transfusion-associated bacterial contamination: results of the French BACTHEM Case-Control Study. Transfusion 2001;41:862-72.
34. Kopko PM, Holland PV. Mechanisms of severe transfusion reactions. Transfus Clin Biol 2001;8:278-81.
35. Brunner S, Frey-Rindova P, Altwegg M, Zbinden R. Retroperitoneal abscess and bacteremia due to Mycoplasma hominis in a polytraumatized man. Infection 2000;28:46-8.
36. Norton R, Mollison L. Mycoplasma hominis pneumonia in aboriginal adults. Pathology 1995;27:58-60.
37. Rosendal S. Experimental infection in goats, sheep and calves with the large colony type of Mycoplasma mycoides subsp. mycoides. Vet Pathol 1981;18:71-81.
38. Lloyd LC, Etheridge JR. Production of arthritis by intravenous inoculation of Mycoplasma hyopneumoniae: tests on five strains. Res Vet Sci 1981;30:124-6.
39. Binder A, Gartner K, Hedrich HJ, et al. Strain differences in sensitivity of rats to Mycoplasma arthritidis ISR 1 infection are under multiple gene control. Infect Immun 1990;58:1584-90.
40. Wollinsky KH, Mehrkens HH, Geiger P, et al. Kinetics of bacterial wash-out in the Haemonetics Cell Saver III. Beitr Infusiosther 1991;28:337-40.
41. Kahn RA, Meryman HT, Syring RL, Flinton LJ. The fate of bacteria in frozen red cells. Transfusion 1976;16:215-20.
42. Siblini L, Lafeuillade B, Ros A, et al. Reduction of Yersinia enterocolitica load in deliberately inoculated blood: the effects of blood prestorage temperature and WBC filtration. Transfusion 2002;42:422-7.